Chronic pelvic pain syndrome
ICD-10 R10.2 · ICD-11 MG30.00

Persistent Prostate Pain in Males When First-Line Multimodal Therapy Has Not Achieved Its Goals

This protocol addresses the next clinical step for males with at least 3 months of persistent or recurrent episodic prostate pain—pain convincingly reproduced by prostate palpation—in the absence of proven infection or other identifiable local pathology, when first-line management has fallen short.

Clinical scenario

Primary prostate pain syndrome is the occurrence of persistent or recurrent episodic pain convincingly reproduced by prostate palpation, with no proven infection or other obvious local pathology. This protocol applies to male patients in whom pain has been present for at least 3 months.

Why this protocol is reached — first-line failure

The preceding step combined antimicrobial therapy (ciprofloxacin, levofloxacin, or tetracycline hydrochloride) with an alpha-blocker, NSAIDs, and acupuncture. When that multimodal regimen does not achieve a reduction in NIH-CPSI total score, a reduction in chronic pelvic pain severity, or an improvement in lower urinary tract voiding symptoms by 6 weeks, escalation to this next-line protocol is indicated.

Next-step approach

At this stage, oral phytotherapy options—including a pollen extract and plant-based preparations evaluated over a 12-week period—form the basis of management, with the clinical goal of reducing NIH-CPSI total score and chronic pelvic pain severity. The complete protocol with all options and guidance is available via the link below.

Instant Access to Structured Evidence-Based Regimens

References

  1. Primary prostate pain syndrome is the occurrence of persistent or recurrent episodic pain (which is convincingly reproduced by prostate palpation).
  2. There is no proven infection or other obvious local pathology.
  3. If antibiotics are used, other therapeutic options should be offered after one unsuccessful course of a quinolone or tetracycline antibiotic over six weeks.
  4. An adequately powered placebo-controlled RCT of a pollen extract (Cernilton) showed clinically significant symptom improvement over a 12-week period in inflammatory PPPS patients (NIH Cat. IIIA).
  5. In a large, multicentre trial of 221 patients over 12 weeks, saw palmetto extract (Serenoa repens) led to statistically significant improvement in the NIH-CPSI total score and sub-scores compared to placebo.
View source ↗